| The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... Cancer discovery, CD-15-1263, 2017 | 342 | 2017 |
| Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo C Thomas, F Lamoureux, C Crafter, BR Davies, E Beraldi, L Fazli, S Kim, ... Molecular cancer therapeutics 12 (11), 2342-2355, 2013 | 145 | 2013 |
| The multifaceted roles of STAT3 signaling in the progression of prostate cancer JL Bishop, D Thaper, A Zoubeidi Cancers 6 (2), 829-859, 2014 | 142 | 2014 |
| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ... Nature cell biology 23 (9), 1023-1034, 2021 | 82 | 2021 |
| Hsp27 regulates EGF/β‐catenin mediated epithelial to mesenchymal transition in prostate cancer T Cordonnier, JL Bishop, M Shiota, KM Nip, D Thaper, S Vahid, D Heroux, ... International journal of cancer 136 (6), E496-E507, 2015 | 78 | 2015 |
| SEMA 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1 JW Peacock, A Takeuchi, N Hayashi, L Liu, KJ Tam, N Al Nakouzi, ... EMBO molecular medicine 10 (2), 219-238, 2018 | 62 | 2018 |
| Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth A Takeuchi, M Shiota, E Beraldi, D Thaper, K Takahara, N Ibuki, M Pollak, ... Molecular and cellular endocrinology 384 (1-2), 117-125, 2014 | 59 | 2014 |
| Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer S Vahid, D Thaper, KF Gibson, JL Bishop, A Zoubeidi Scientific reports 6 (1), 31842, 2016 | 55 | 2016 |
| ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer S Nouruzi, D Ganguli, N Tabrizian, M Kobelev, O Sivak, T Namekawa, ... Nature Communications 13 (1), 2282, 2022 | 44 | 2022 |
| Targeting Lyn regulates Snail family shuttling and inhibits metastasis D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ... Oncogene 36 (28), 3964-3975, 2017 | 36 | 2017 |
| Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer A Zardan, KM Nip, D Thaper, P Toren, S Vahid, E Beraldi, L Fazli, ... Oncogenesis 3 (8), e115-e115, 2014 | 36 | 2014 |
| Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer D Thaper, S Vahid, R Kaur, S Kumar, S Nouruzi, JL Bishop, M Johansson, ... Scientific reports 8 (1), 17307, 2018 | 34 | 2018 |
| PEG10 is associated with treatment-induced neuroendocrine prostate cancer S Kim, D Thaper, S Bidnur, P Toren, S Akamatsu, JL Bishop, C Colins, ... Journal of Molecular Endocrinology 63 (1), 39-49, 2019 | 28 | 2019 |
| Chaperoning the cancer: the proteostatic functions of the heat shock proteins in cancer S Vahid, D Thaper, A Zoubeidi Recent Patents on Anti-Cancer Drug Discovery 12 (1), 35-47, 2017 | 24 | 2017 |
| First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer. DL Thaper, R Munuganti, S Nouruzi, S Kumar, S Kim, S Vahid, O Sivak, ... Journal of Clinical Oncology 37 (7_suppl), 260-260, 2019 | 3 | 2019 |
| Reduction in PD-L1 expression by STAT3 inhibition with GPA500 in enzalutamide-resistant prosate cancer. JL Bishop, DL Thaper, S Vaheid, MH Johansson, A Zoubeidi Journal of Clinical Oncology 33 (15_suppl), e16075-e16075, 2015 | 3 | 2015 |
| Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer G Kumar, E Ritch, HZ Oo, CK Wang, D Tortora, D Thaper, I Moskalev, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020 | 2 | 2020 |
| Neural transcription factors in disease progression D Thaper, S Vahid, A Zoubeidi Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and …, 2019 | 2 | 2019 |
| Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer D Thaper, R Munuganti, A Aguda, S Kim, S Ku, O Sivak, S Kumar, S Vahid, ... bioRxiv, 2022.05. 04.490172, 2022 | 1 | 2022 |
| New derivative of galiellalactone inhibits the STAT3 activity and suppresses ENZ-resistant Prostate Cancer in vitro D Thaper, S Vahid, JL Bishop, M Johansson, A Zoubeidi Cancer Research 75 (15_Supplement), 728-728, 2015 | 1 | 2015 |
Amina ZoubeidiUniversity of British ColumbiaVerified email at prostatecentre.com
